Oculis (NASDAQ:OCS) Posts Earnings Results, Misses Estimates By $0.08 EPS

Oculis (NASDAQ:OCS) released its earnings results on Tuesday. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.08), Zacks reports. The business had revenue of $0.50 million for the quarter, compared to analyst estimates of $0.14 million. Oculis had a negative return on equity of 67.89% and a negative net margin of 8,173.41%.

Oculis Stock Performance

NASDAQ:OCS traded up $0.07 during mid-day trading on Thursday, reaching $27.79. 237,706 shares of the company’s stock were exchanged, compared to its average volume of 310,987. Oculis has a one year low of $14.00 and a one year high of $30.68. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.47 and a current ratio of 4.47. The business’s fifty day simple moving average is $25.89 and its two-hundred day simple moving average is $21.44. The firm has a market capitalization of $1.46 billion, a PE ratio of -12.24 and a beta of 0.29.

Institutional Investors Weigh In On Oculis

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Perceptive Advisors LLC acquired a new stake in shares of Oculis during the 4th quarter worth approximately $9,862,000. Millennium Management LLC acquired a new stake in Oculis in the fourth quarter worth $312,000. Marshall Wace LLP acquired a new stake in Oculis in the fourth quarter worth $914,000. Alyeska Investment Group L.P. increased its stake in Oculis by 152.3% in the fourth quarter. Alyeska Investment Group L.P. now owns 331,332 shares of the company’s stock valued at $6,617,000 after purchasing an additional 200,000 shares in the last quarter. Finally, HRT Financial LP acquired a new position in shares of Oculis during the fourth quarter valued at about $876,000. 22.30% of the stock is currently owned by institutional investors.

Key Headlines Impacting Oculis

Here are the key news stories impacting Oculis this week:

• Positive Sentiment: Privosegtor received Breakthrough Therapy designation and Oculis is advancing registrational programs in optic neuropathies — this materially improves the regulatory and commercial outlook for a high-value neuro‑ophthalmology asset. Article Title
• Positive Sentiment: Topline readout for OCS-01 (DIAMOND Phase 3 in diabetic macular edema) is on track for Q2 2026 — a successful result would be a major value inflection and potential first‑in‑class topical DME therapy. Article Title
• Positive Sentiment: Strong reported cash position (cash, cash equivalents & short‑term investments ~$268.7M) — company says runway into 2029, which lowers near‑term financing risk ahead of multiple pivotal readouts. Article Title
• Positive Sentiment: Street momentum: recent analyst price‑target increases (HC Wainwright to $44, Needham to $40) and several buy/outperform ratings improve sentiment and can attract more institutional flows. Article Title
• Positive Sentiment: Large institutional buying reported (Wellington, Saturn V, Aberdeen, Perceptive, SR One, others added substantial positions) — this indicates conviction from health‑care investors and supports the rally. Article Title
• Neutral Sentiment: Management will present at multiple March investor conferences (Leerink, LifeSci, one‑on‑ones) — useful for visibility and Q&A but outcome-dependent. Article Title
• Neutral Sentiment: Company filed audited 2025 consolidated financial statements / Form 20‑F — improves disclosure and transparency; not an immediate earnings catalyst. Article Title
• Neutral Sentiment: Company renewed a $100M ATM program — provides optional financing flexibility but can imply potential dilution if used. Article Title
• Negative Sentiment: Q4 EPS missed estimates (loss $0.51 vs. consensus -$0.43) despite a revenue beat — reinforces that near‑term GAAP profitability is distant and raises short‑term volatility risk around financing/operational execution. Article Title
• Negative Sentiment: Insider RSU vesting/settlement notices were published — creates small near‑term selling overhang depending on lockups and insider selling intentions. Article Title

Wall Street Analyst Weigh In

A number of research firms have recently commented on OCS. Wall Street Zen upgraded Oculis from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. Lifesci Capital assumed coverage on shares of Oculis in a research report on Wednesday, December 3rd. They set an “outperform” rating and a $55.00 target price for the company. Bank of America reduced their price target on shares of Oculis from $30.00 to $29.00 and set a “buy” rating on the stock in a research report on Thursday, November 13th. HC Wainwright boosted their price objective on shares of Oculis from $42.00 to $44.00 and gave the stock a “buy” rating in a research note on Wednesday. Finally, Needham & Company LLC raised their target price on shares of Oculis from $36.00 to $40.00 and gave the company a “buy” rating in a research note on Wednesday. Eight analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $43.50.

About Oculis

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.